Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
- PMID: 10337991
- DOI: 10.1002/(sici)1098-2264(199906)25:2<91::aid-gcc3>3.0.co;2-5
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
Abstract
We screened 81 ovarian tumours (30 BRCA1 associated, 18 BRCA2 associated, and 33 sporadic) for somatic TP53 mutations using both DNA analysis and immunostaining. TP53 mutations were significantly more frequent in tumours with mutations in BRCA1 (70% by immunostaining and 60% by DNA analysis) and BRCA2 (67% and 50%) compared to sporadic controls (39% and 30%) (P = 0.009). A higher proportion of tumours with BRCA1 and BRCA2 mutations were poorly differentiated, and TP53 mutant tumours in all categories were also more likely to be poorly differentiated. The poor differentiation of tumours with BRCA1 and BRCA2 mutations may be directly related to the role of these genes in DNA repair, and the need to overcome cell cycle checkpoints, often through loss of TP53. These results are consistent with the model of BRCA-induced tumorigenesis in which loss of checkpoint control is necessary for tumour development.
Similar articles
-
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.Oncogene. 1998 Oct 1;17(13):1681-9. doi: 10.1038/sj.onc.1202106. Oncogene. 1998. PMID: 9796697
-
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.J Clin Pathol. 1999 May;52(5):372-5. doi: 10.1136/jcp.52.5.372. J Clin Pathol. 1999. PMID: 10560359 Free PMC article.
-
Is TP53 dysfunction required for BRCA1-associated carcinogenesis?Mol Cell Endocrinol. 1999 Sep 10;155(1-2):143-52. doi: 10.1016/s0303-7207(99)00117-3. Mol Cell Endocrinol. 1999. PMID: 10580847 Review.
-
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.Cancer Res. 1998 Aug 1;58(15):3193-6. Cancer Res. 1998. PMID: 9699640
-
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.Hum Mol Genet. 2001 Apr;10(7):705-13. doi: 10.1093/hmg/10.7.705. Hum Mol Genet. 2001. PMID: 11257103 Review.
Cited by
-
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.BMC Cancer. 2005 Oct 17;5:134. doi: 10.1186/1471-2407-5-134. BMC Cancer. 2005. PMID: 16229746 Free PMC article.
-
The mammalian ovary from genesis to revelation.Endocr Rev. 2009 Oct;30(6):624-712. doi: 10.1210/er.2009-0012. Epub 2009 Sep 23. Endocr Rev. 2009. PMID: 19776209 Free PMC article. Review.
-
Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?J Vet Sci. 2010 Dec;11(4):291-7. doi: 10.4142/jvs.2010.11.4.291. J Vet Sci. 2010. PMID: 21113097 Free PMC article.
-
Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.PLoS One. 2009 Dec 31;4(12):e8534. doi: 10.1371/journal.pone.0008534. PLoS One. 2009. PMID: 20046869 Free PMC article.
-
BRCA mutations in the manifestation and treatment of ovarian cancer.Onco_target. 2017 May 30;8(57):97657-97670. doi: 10.18632/onco_target.18280. eCollection 2017 Nov 14. Onco_target. 2017. PMID: 29228641 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous